Enter your keyword

Efficiently Creating Value with Innovative Science

Press Release

Aug 30, 2018
Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications, today announced it will provide an overview of the company and its programs at the 20th Annual Rodman & Renshaw Global Investment Conference.

Mateon's presentation is scheduled to occur on Thursday, September 6, 2018 at 3:00 p.m. eastern time. To listen to a live webcast of the presentation, please visit the Company's website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at the same location following the conclusion of the live event.

About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, with programs in acute myeloid leukemia and immuno-oncology. Mateon is committed to leveraging its product development expertise and intellectual property to bring improved and medically necessary new therapies to cancer patients worldwide.


Mateon Therapeutics, Inc.
Matthew M. Loar

Primary Logo

Source: Mateon Therapeutics

News Provided by Acquire Media